Approval · Notice of Compliance 22003 · 2019
ENABLEX: Notice of Compliance 22003
Issued March 25, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22003
- Date
- March 25, 2019
- Company
- Searchlight Pharma Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Approval to design a change to the inner blister label for the 7.5 mg strength
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENABLEX | Not yet assigned | — |
Medicinal ingredients
- DARIFENACIN HYDROBROMIDE 7.5 MG per TAB